Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study
about
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineAdult immunization-Need of the hourSystematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble saltsThe potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programmeEfficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Safety of human papillomavirus vaccines: a review.Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.Modeling optimal cervical cancer prevention strategies in Nigeria.Alternative dosage schedules with HPV virus-like particle vaccines.The rise (and fall?) of parental vaccine hesitancyHuman papilloma virus vaccination: impact and recommendations across the world.A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov modelQuantifying clinical HPV4 dose inefficiencies in a safety net populationImmunoprevention of human papillomavirus-associated malignanciesThe case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.Human papillomavirus vaccination: current indications and future directionsReduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in ScotlandCost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Parents' decision-making about the human papillomavirus vaccine for their daughters: II. Qualitative results.Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).A review of clinical trials of human papillomavirus prophylactic vaccines.Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.[Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis].HPV vaccine: One, two, or three doses for cervical cancer prevention?An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c micePredictors of Human Papillomavirus Vaccination in a Large Clinical Population of Males Aged 11 to 26 years in Maryland, 2012-2013Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized studyImmunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsTen years of anti-HPV vaccinations: what do we know?Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United StatesHuman papillomavirus vaccination: where are we now?
P2860
Q26749285-B31969CD-F28B-444E-9F83-B8D4AD4D81ECQ28077096-CAB10DF1-A347-4823-87F0-C12904C60FE4Q28387541-4C9D5C60-CE83-4577-BE1F-64A36FD5A062Q30251408-A0B8F5F0-ECAA-466C-BC48-980D1CE33C9CQ30780649-245E9E18-F509-48AB-98CD-3660E80DBAA0Q30970916-F588101C-9C0E-4E39-8B1E-CA2CE11DB162Q30980654-A58ECA66-7B69-4060-8C28-3E2EB82FF3F3Q33162724-2BF89454-7FF4-4A86-ABC4-1EB6799E8CE1Q33724422-6073965A-E902-4607-8370-07FD4F0827CAQ33755002-3F39C6EA-5D45-40E3-B7AE-05F1709BCDB4Q34102466-10DEC81D-FCB6-4762-AF94-C5579B33F7AAQ34349193-A05085D5-D10C-4663-BB24-6648764E74AAQ34704575-20AAA1E4-9D2B-4528-AEF1-B2F5F617DB75Q34708325-7FEF5BE2-189E-4C05-A752-C7CB9FBF6171Q34894228-38978AEF-1406-4758-AC1D-2BC7DD98D32DQ35040145-D107AF1A-6EEB-41CF-A498-B6C90B3583A5Q35044376-A9AA29A5-584E-4D3C-8A6B-AE070788CD75Q35078557-29A5D20F-3875-4865-A6A9-84CDBCEF946DQ35558593-CEA9DA24-8C20-4A18-A4D2-AC503617D779Q35678090-DA6F39B2-DDE4-45B4-9759-CF25B4F41059Q35865134-35508109-2320-4F97-902B-77FD2389AF8BQ35886910-FB710A5B-DF2E-4305-AAAC-492532069E39Q35887704-356D7053-BB75-4184-A9A1-B441A1F261B8Q35902534-F52C527E-DA22-4E77-AC99-A5046661367AQ36256554-8A4AEE58-CC9A-4D8B-863E-0E7605D3A5F6Q36259403-5C104D2B-135E-43AE-B47D-B00E33382236Q36266671-3A279EA3-C7FB-4891-847F-572D37A78379Q36373370-52CDFD14-B903-44A2-B378-EF23E890270FQ36388694-EC48E48D-2761-46EE-A925-B48907A60DF4Q36457994-3D4A8F78-7F59-45CC-AE8C-DEAC0C4D7E19Q36500189-160BFC76-37AE-4BEC-A892-CEE6F92864D4Q36619758-1061C9CD-874C-44EA-A2E2-E6887503CA30Q36977720-9E6889C6-6182-44D2-8E64-319D06F6D524Q36978399-4813BF9F-AAD0-4A57-AE66-600A1B75E871Q37118381-8B069901-5FA4-42B2-9C43-22317F684FF2Q37135074-97798349-7B80-4A08-A6DE-60DF3B640BB0Q37135276-D4CBF195-76FE-4A8E-B847-47D760EAB8C2Q37473145-E72E7D94-77F2-48D3-9B38-BE9BEFEC3492Q37721457-F898B68F-95BE-48DE-A9D3-125A310DF95BQ38218612-607543CE-6FEB-44C2-ADB5-5FC3448A61BC
P2860
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Immunogenicity and safety of t ...... esults from a randomized study
@ast
Immunogenicity and safety of t ...... esults from a randomized study
@en
type
label
Immunogenicity and safety of t ...... esults from a randomized study
@ast
Immunogenicity and safety of t ...... esults from a randomized study
@en
prefLabel
Immunogenicity and safety of t ...... esults from a randomized study
@ast
Immunogenicity and safety of t ...... esults from a randomized study
@en
P2093
P2860
P356
P1433
P1476
Immunogenicity and safety of t ...... esults from a randomized study
@en
P2093
Anne Schuind
Barbara Romanowski
Brian Ramjattan
Dominique Descamps
Grégory Catteau
Karin Schulze
Klaus Peters
Kurt Dobbelaere
Linda M Ferguson
Marc Dionne
P2860
P304
P356
10.4161/HV.7.12.18322
P577
2011-12-01T00:00:00Z